Business

Know the Business

Bottom line. Cooper is a two-engine medical device company: CooperVision (67% of sales) is a genuinely good business — a global soft contact lens oligopolist with 66% gross margins, recurring single-use refills, and a decade of steady share gains from Biofinity, MyDay and MiSight. CooperSurgical (33%) is the drag — a roll-up of ~600 fertility and women's-health SKUs that delivers only half the margin and has just absorbed $343M of acquisition integration pain. The market is probably overestimating the threat of GLP-1s and LASIK to contact lens demand, and underestimating how much of Cooper's reported earnings volatility is amortization of Surgical deal intangibles rather than true economic cost.

How This Business Actually Works

CooperVision sells a consumable that patients replace on a prescription-locked schedule; CooperSurgical sells into a fragmented specialty-procedure market it is trying to consolidate through acquisition.

The CVI engine is simple and attractive: a patient walks into an optometrist, gets a prescription, and then re-orders the same SKU every 1 day, 2 weeks, or 1 month for years. Cooper competes against only three other serious players globally — J&J Vision, Alcon and Bausch + Lomb. Manufacturing runs through a tight network (Belgium, Costa Rica, Hungary, Puerto Rico, the UK and the US); single-use silicone hydrogel is the fastest-growing modality and where Cooper has a full product lineup (MyDay premium, clariti value). The incremental dollar drops through at ~35-40% operating margin because the factory is already paid for, the SKU is already stocked at the optical chain, and the optometrist's switching cost for the patient is real.

MiSight is the interesting call option. It is the only FDA-, NMPA- and now MHLW-approved (Japan, August 2025) contact lens to slow myopia progression in 8-12 year-olds. Premium pricing, sticky 3-6 year treatment plans, and a standard-of-care narrative in pediatric optometry. Still small but growing fast — management called out "early traction" on MyDay MiSight in Q1 FY26.

The CSI engine is the opposite of elegant. It is 600+ SKUs assembled by acquisition since 1990, sold through OB/GYNs, surgery centers and fertility clinics. Two sub-pieces:

1. Office/Surgical ($824M, 61% of CSI) — Paragard (the only hormone-free IUD in the US, ~17% IUD share), cord blood/tissue storage, and a long tail of gynecology instruments. This is defended by a regulated drug-device combo (Paragard) plus OB/GYN channel relationships.
2. Fertility ($525M, 39% of CSI) — IVF consumables, media, micro-tools, donor gametes, cryostorage and genetic testing. End market grows on demographics (rising maternal age, infertility rates, access) but is fragmented and competes with Vitrolife, Fairfax Cryobank and a long tail.

CSI's operating margin collapsed from 9% to 3% in FY25 because of write-offs, severance and amortization from the Cook Medical and obp Surgical acquisitions. On a non-GAAP basis the underlying margin is closer to low-20s — not 3% — but the point stands: CSI is a harder business than CVI and every dollar of incremental revenue there drops through at roughly half the rate.

The Playing Field

Among big-cap device peers, Cooper sits at the cheaper, lower-growth end of the quality spectrum — good margins, middling returns, too much deal amortization suppressing reported ROE.

What this reveals. Edwards (EW) is the aspirational benchmark for a focused device company: 78% gross margin, 27% operating margin, 50% ROIC because TAVR is a monopoly-economics category. Cooper is not that — soft contact lenses are a healthy oligopoly, not a monopoly, and CSI is a multi-category roll-up. Hologic posts a 67% ROIC but that number is flattered by a small asset base post-impairments; it is not a like-for-like compounder. Alcon is the clearest direct comparator on CVI — similar gross margin, similar ~25% contact lens share, but Alcon carries a surgical-equipment business with lower gross margins. Bausch + Lomb is a post-spin mess with a weak balance sheet; it sets the floor, not the ceiling.

Cooper's reported ROE of 14% looks pedestrian, but the denominator is inflated by acquisition goodwill. On a cash-return basis (FCF / invested capital ex-goodwill), the CVI segment is a high-teens to low-20s business. Reported ROIC of 23% (Joel Greenblatt basis) reflects that once you strip accounting intangibles.

Is This Business Cyclical?

Cyclical at the edges, not at the core. Contact lens wearers do not suddenly stop wearing lenses in a recession — the base is recurring and prescription-anchored. What moves with the cycle is new fittings (discretionary optometrist visits), premium product mix (dailies over monthlies, MiSight over standard lenses), and elective fertility treatment (IVF cycles are $15-20K out-of-pocket in the US). So demand dips 3-8% in a bad year, not 25%.

The 2020 downturn is the cleanest recent test. COVID shut optometrist offices and paused IVF clinics for most of Q2-Q3 FY20. Revenue fell 8% ($2.65B to $2.43B) and operating margin compressed from 20% to 13% — painful but not catastrophic, and fully recovered by FY21. The 2007-2009 credit cycle barely registered on contact lens demand. The real pressure points are FX (roughly half of sales are outside the US) and interest expense — Cooper carried $2.5B gross debt into FY25 at rate-hike era yields, and $100-114M of annual interest absorbs 2-3 points of net margin.

One cycle-ish risk worth flagging: CSI's fertility sub-segment is more discretionary than contact lenses. IVF cycle counts in the US fell ~15% during 2020 and again softened in 2023-24 when consumer savings normalized. Not a vision-style recession but not recession-proof either.

The Metrics That Actually Matter

Five numbers tell you more about Cooper's value creation than the whole 10-K.

The single most important metric to watch quarterly is CVI organic revenue growth. Every other line item follows from it. If CVI organic drops below 4% for two quarters in a row, that is the first real signal that either (a) contact lens wearers are being poached by J&J's 1-DAY Acuvue Oasys Max or Alcon's Precision1, or (b) the broader wearer base is eroding from LASIK/SMILE surgery or GLP-1-induced vision changes — both theses the bears love and neither currently showing up in the data (Q1 FY26 CVI organic: +3%, a tick below trend, FX-dominated geography impact).

What I'd Tell a Young Analyst

Value Cooper as two companies. Do a sum-of-parts: put CVI on 18-22x EV/EBITDA (its peers Alcon and J&J Vision Care trade there), put CSI on 11-14x (roll-ups of women's health and fertility IP rarely get more), add the net cash or subtract the net debt, and compare to where COO trades as a blended multiple. Today's ~14x blended EV/EBITDA implicitly values CSI too cheaply or CVI in line — meaning the stock compounds if CVI keeps growing 5-7% organically and CSI margins just normalize back to FY23 levels.

What to watch, ranked: (1) CVI organic growth and the single-use mix shift — these are the value creators; (2) MiSight uptake especially in Japan where MHLW approval just landed and the myopia population is 40%+ of school-age children; (3) CSI segment operating margin recovering from 3% — this is optionality, not the base case; (4) interest expense trajectory as the 2021 Term Loan refinances before December 2026; (5) FX — roughly half of sales are ex-US, so a strong dollar clips 3-5% off reported growth.

What the market may be missing. The bears' LASIK/GLP-1/digital-vision narrative has been around for twenty years and the installed base of soft contact lens wearers has grown through all of it. The more credible bear case is not demand destruction but competitive displacement — J&J and Alcon both launched premium dailies in 2023-24 with claims of better comfort metrics, and if Cooper's MyDay premium lineup doesn't refresh fast enough, unit share can leak even as the category grows.

What would change the thesis. CVI organic growth under 3% for a full year. A Paragard-style blockbuster issue on any of the IVF/cryostorage product lines (litigation, recall). A material impairment on Cook Medical goodwill within three years of the deal closing. The dividend was cut in December 2023 to redirect cash to buybacks — a reversal (restoring the dividend under pressure) would signal management has run out of M&A opportunities that beat buybacks, which is actually the moment the stock gets more interesting, not less.